• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report.

作者信息

Jennes Serge, Merabishvili Maia, Soentjens Patrick, Pang Kim Win, Rose Thomas, Keersebilck Elkana, Soete Olivier, François Pierre-Michel, Teodorescu Simona, Verween Gunther, Verbeken Gilbert, De Vos Daniel, Pirnay Jean-Paul

机构信息

Burn wound center, Queen Astrid military hospital, Brussels, Belgium.

Laboratory for molecular and cellular technology, Queen Astrid military hospital, Brussels, Belgium.

出版信息

Crit Care. 2017 Jun 4;21(1):129. doi: 10.1186/s13054-017-1709-y.

DOI:10.1186/s13054-017-1709-y
PMID:28583189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5460490/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09d5/5460490/4b39ab6df2d5/13054_2017_1709_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09d5/5460490/581a23863e52/13054_2017_1709_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09d5/5460490/4b39ab6df2d5/13054_2017_1709_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09d5/5460490/581a23863e52/13054_2017_1709_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09d5/5460490/4b39ab6df2d5/13054_2017_1709_Fig2_HTML.jpg

相似文献

1
Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report.噬菌体在一名急性肾损伤患者的仅对黏菌素敏感的铜绿假单胞菌败血症治疗中的应用——病例报告
Crit Care. 2017 Jun 4;21(1):129. doi: 10.1186/s13054-017-1709-y.
2
Current therapies for pseudomonas aeruginosa.铜绿假单胞菌的当前治疗方法。
Crit Care Clin. 2008 Apr;24(2):261-78, viii. doi: 10.1016/j.ccc.2007.12.004.
3
Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.在耐多药铜绿假单胞菌血症患者中，联合使用黏菌素和环丙沙星进行治疗时，因环丙沙星耐药性产生导致治疗失败。
Int J Antimicrob Agents. 2014 Apr;43(4):391-3. doi: 10.1016/j.ijantimicag.2014.01.020. Epub 2014 Feb 22.
4
[Clinical and therapeutic features of pseudomonas aeruginosa septicaemia].[铜绿假单胞菌败血症的临床与治疗特征]
Dtsch Med Wochenschr. 1972 Oct 20;97(42):1584-9. doi: 10.1055/s-0028-1107608.
5
Colistin: an antimicrobial for the 21st century?黏菌素：21世纪的抗菌药物？
Clin Infect Dis. 2002 Oct 1;35(7):901-2. doi: 10.1086/342570.
6
Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician.多药耐药铜绿假单胞菌血流感染中的黏菌素：临床医生的叙述性综述。
J Infect. 2014 Jul;69(1):1-12. doi: 10.1016/j.jinf.2014.03.001. Epub 2014 Mar 11.
7
Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa.抗生素联合治疗铜绿假单胞菌所致实验性脓毒症的疗效。
Braz J Microbiol. 2023 Dec;54(4):2817-2826. doi: 10.1007/s42770-023-01141-9. Epub 2023 Oct 13.
8
S-thanatin in vitro prevents colistin resistance and improves its efficacy in an animal model of Pseudomonas aeruginosa sepsis.S-Thanatin 体外预防粘菌素耐药并提高其在铜绿假单胞菌脓毒症动物模型中的疗效。
Peptides. 2011 Apr;32(4):697-701. doi: 10.1016/j.peptides.2011.01.016. Epub 2011 Jan 22.
9
The clinical use of colistin in patients with cystic fibrosis.黏菌素在囊性纤维化患者中的临床应用。
Curr Opin Pulm Med. 2001 Nov;7(6):434-40. doi: 10.1097/00063198-200111000-00013.
10
Intrathecal colistin for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa after neurosurgical ventriculitis.鞘内注射黏菌素治疗神经外科脑室炎后多重耐药铜绿假单胞菌感染
Infez Med. 2010 Sep;18(3):182-6.

引用本文的文献

1
Biocontrol of Phage Resistance in Infections: Insights into Directed Breaking of Spontaneous Evolutionary Selection in Phage Therapy.感染中噬菌体抗性的生物防治：噬菌体疗法中定向打破自发进化选择的见解
Viruses. 2025 Aug 4;17(8):1080. doi: 10.3390/v17081080.
2
Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: and barrier-overcoming strategies.用于治疗肺部感染的基于可吸入纳米颗粒的递送系统及克服屏障的策略。
Drug Deliv. 2025 Dec;32(1):2544683. doi: 10.1080/10717544.2025.2544683. Epub 2025 Aug 11.
3
Applications of bacteriophages in precision engineering of the human gut microbiome.

本文引用的文献

1
Safety and efficacy of phage therapy via the intravenous route.静脉途径噬菌体疗法的安全性和有效性。
FEMS Microbiol Lett. 2016 Feb;363(3). doi: 10.1093/femsle/fnv242. Epub 2015 Dec 20.
2
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.《世界医学协会赫尔辛基宣言：涉及人类受试者的医学研究伦理原则》
JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053.
3
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.
噬菌体在人类肠道微生物组精准工程中的应用。
Eng Microbiol. 2025 Jan 6;5(1):100189. doi: 10.1016/j.engmic.2025.100189. eCollection 2025 Mar.
4
[Potential of bacteriophage therapy in Germany: evidence and clinical relevance].[德国噬菌体疗法的潜力：证据与临床相关性]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Apr 28. doi: 10.1007/s00103-025-04048-y.
5
Addressing the Research and Development Gaps in Modern Phage Therapy.填补现代噬菌体疗法中的研发空白。
Phage (New Rochelle). 2024 Mar 18;5(1):30-39. doi: 10.1089/phage.2023.0045. eCollection 2024 Mar.
6
Emerging antimicrobial therapies for Gram-negative infections in human clinical use.目前正在临床应用的针对革兰氏阴性菌感染的新型抗菌疗法。
NPJ Antimicrob Resist. 2025 Feb 27;3(1):16. doi: 10.1038/s44259-025-00087-2.
7
Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.噬菌体及其产物作为抗菌剂的再度兴起：概述
Int J Mol Sci. 2025 Feb 19;26(4):1755. doi: 10.3390/ijms26041755.
8
Early Detection, Diagnosis, Prevention, and Treatment of Infection to Avoid Sepsis and Septic Shock in Severely Burned Patients: A Narrative Review.严重烧伤患者感染的早期检测、诊断、预防及治疗以避免脓毒症和感染性休克：一篇叙述性综述
Eur Burn J. 2025 Feb 6;6(1):6. doi: 10.3390/ebj6010006.
9
Multi-strain phage induced clearance of bacterial infections.多菌株噬菌体诱导清除细菌感染。
PLoS Comput Biol. 2025 Feb 4;21(2):e1012793. doi: 10.1371/journal.pcbi.1012793. eCollection 2025 Feb.
10
In Vitro Susceptibility of Clinical and Carrier Strains of to STAFAL Phage Preparation.临床菌株和携带菌株对STAFAL噬菌体制剂的体外敏感性
Int J Mol Sci. 2024 Nov 29;25(23):12885. doi: 10.3390/ijms252312885.
用于人体临床试验的经过质量控制的特定噬菌体混合物的小规模生产。
PLoS One. 2009;4(3):e4944. doi: 10.1371/journal.pone.0004944. Epub 2009 Mar 20.